Mangoceuticals
MGRX
1 hedge funds and large institutions have $5.32K invested in Mangoceuticals in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$11K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $5.32K | +$11K | +311 | New |
|
MGRX Hedge Fund Activity: Q1 2023 in Review
1 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in Mangoceuticals (MGRX) for Q1 2023, worth a combined $5.32K.
Buyers outnumbered sellers: 1 fund opened new MGRX positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $11K.
- 1 institutional investor held Mangoceuticals (MGRX) as of Q1 2023, up from 0 in Q4 2022.
- Funds reported $5.32K of Mangoceuticals stock for Q1 2023.
- 1 fund opened new Mangoceuticals positions in Q1 2023 and 0 closed out, a net change of +1 holder.
- The largest Mangoceuticals buyer in Q1 2023 was UBS Group, an estimated $11K added.
Based on aggregated 13F filings for Q1 2023.